Prognostic value of combined serum biomarkers in predicting outcomes in cervical cancer patients
| Autor: | Yaping Tian, Zhennan Dong, Juan Li, Hongli Tong, Fei Guo, Hao Cheng, Pengjun Zhang, Jing-Dong J. Han |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Oncology Cart medicine.medical_specialty Pathology Multivariate analysis Clinical Biochemistry Gene Expression Uterine Cervical Neoplasms Disease Adenocarcinoma Biochemistry Carcinoma Adenosquamous Antigens Neoplasm Serum biomarkers Internal medicine Biomarkers Tumor medicine Humans In patient Serpins Aged Neoplasm Staging Proportional Hazards Models Retrospective Studies Cervical cancer Tumor Necrosis Factor-alpha Proportional hazards model business.industry Mucin-1 Biochemistry (medical) General Medicine Middle Aged Prognosis medicine.disease Survival Analysis Case-Control Studies Carcinoma Squamous Cell Female Tumor necrosis factor alpha business |
| Zdroj: | Clinica Chimica Acta. 424:292-297 |
| ISSN: | 0009-8981 |
| DOI: | 10.1016/j.cca.2013.07.003 |
| Popis: | We evaluated the prognostic value of pretreatment serum biomarkers in predicting outcomes in cervical cancer patients subjected to treatment.Serum samples collected from 60 cervical cancer patients and 60 age-matched healthy individuals were used for the detection of 22 biomarkers, prior to therapy. Cox multivariate analysis and classification and regression tree analysis (CART) were performed to evaluate the prognostic factors.Cox multivariate analysis disclosed that carbohydrate antigen 153 (CA153), squamous cell carcinoma antigen (SCC) and tumor necrosis factor-α (TNF-α) are associated with prognosis in cervical cancer. CART analysis led to the stratification of patients into 3 groups: (1) serum concentrations of CA153 ≥17.60 μg/l, (2) serum concentrations of CA15317.60 μg/l and TNF-α ≥10.60 pg/ml, and (3) serum concentrations of CA15317.60 μg/l and TNF-α10.60 pg/ml. The 2-y overall survival rates for Groups 1, 2 and 3 were 33.3%, 60.0% and 93.9%, respectively.Higher serum concentrations of TNF-α, SCC and CA153 before therapy are independently associated with poor prognosis in patients with stage I and II disease. Combined usage of these three biomarkers allows efficient evaluation of outcomes in cervical cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect